Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.

Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
A
A

Amgen

Ειδήσεις

Reuters - 5 ημέρες πριν

Viridian Therapeutics rises after upsized $225 mln stock offering

BUZZ-Viridian Therapeutics rises after upsized $225 mln stock offering ** Viridian Therapeutics VRDN.O shares up 1.1% at $20.02 after co's equity haul exceeds expectations ** Co late Weds announced pricing ~10.7 mln shares at $18.75 and preferred stock convertible into ~1.3 mln shares for $225 mln gross proceeds ** Deal size increased from planned $150 mln raise ** VRDN shares on Tues popped ~32% after co's drug, veligrotug, significantly reduced thyroid eye disease (TED) symptoms in late-stage
A
Reuters - 1 εβδομάδα πριν

Weight-loss market to see 16 new drugs by 2029, report estimates

Weight-loss market to see 16 new drugs by 2029, report estimates Sept 10 (Reuters) - The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N , according to estimates from analysts at Morningstar and Pitchbook. In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031. The 16 drugs could launch by 2029, wi
A
P
R
Reuters - 1 εβδομάδα πριν

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
A
C
P
T
Reuters - 1 εβδομάδα πριν

Viridian's drug cuts thyroid eye disease symptoms in late-stage study

UPDATE 3-Viridian's drug cuts thyroid eye disease symptoms in late-stage study Shares rise 14% as drug meets main and secondary goals Analysts highlight less frequent dosing as a key advantage Jefferies estimates potential peak sales of $2 billion Adds analyst comment in paragraphs 3-5 and paragraph 9, background on disease throughout By Mariam Sunny Sept 10 (Reuters) - Viridian Therapeutics VRDN.O said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye dis
A
Reuters - 1 εβδομάδα πριν

Amgen Presents New Data For First-In-Class IMDELLTRA (tarlatamab-dlle) In Small Cell Lung Cancer At WCLC 2024

BRIEF-Amgen Presents New Data For First-In-Class IMDELLTRA (tarlatamab-dlle) In Small Cell Lung Cancer At WCLC 2024 Sept 9 (Reuters) - Amgen Inc AMGN.O : AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 AMGEN INC - DELLPHI-301 LONG-TERM FOLLOW-UP DATA DEMONSTRATE SUSTAINED SAFETY AND E
A
Reuters - 2 εβδομάδες πριν

Amgen aims to treat liver, kidney diseases with obesity drug

UPDATE 2-Amgen aims to treat liver, kidney diseases with obesity drug Adds details and background throughout By Puyaan Singh Sept 4 (Reuters) - Amgen AMGN.O will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said on Wednesday.
A
Reuters - 2 εβδομάδες πριν

Amgen to test its obesity drug in patients at risk of obesity-related diseases

Amgen to test its obesity drug in patients at risk of obesity-related diseases Sept 4 (Reuters) - Amgen AMGN.O will test its obesity drug candidate in patients at risk of obesity-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said at a Morgan Stanley healthcare conference on Wednesday.
A
Reuters - 2 εβδομάδες πριν

US will still pay at least twice as much after negotiating drug prices

UPDATE 1-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation Updates first graphic to align colors representing countries with second graphic By Deena Beasley Sept 3 (Reuters) - The U.S.
A
A
B
N
P
Reuters - 2 εβδομάδες πριν

US will still pay at least twice as much after negotiating drug prices

ANALYSIS-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation By Deena Beasley Sept 3 (Reuters) - The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income count
A
A
B
N
P
Reuters - 3 εβδομάδες πριν

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year By Patrick Wingrove Aug 26 (Reuters) - Cigna CI.N said on Monday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
A
C
P
T
Reuters - 4 εβδομάδες πριν

Otezla Now Available In The US For Moderate To Severe Pediatric Plaque Psoriasis

BRIEF-Otezla Now Available In The US For Moderate To Severe Pediatric Plaque Psoriasis Aug 20 (Reuters) - Amgen Inc AMGN.O : OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS Source text for Eikon: ID:nPn8knQCca Further company coverage: AMGN.O
A
Reuters - 4 εβδομάδες πριν

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D
Reuters - 1 μήνα πριν

Reactions to Medicare's drug price cuts

QUOTES-Reactions to Medicare's drug price cuts Aug 15 (Reuters) - The U.S. government said on Thursday it had negotiated down the prices of 10-top selling prescription drugs by as much as 79% for the Medicare health program for older Americans, ending months of unprecedented discussions with drugmakers. The U.S. government expects to save $6 billion in the first year from the new prices negotiated through provisions of the Inflation Reduction Act that allow Medicare for the most costly drugs tha
A
A
N
P
Reuters - 1 μήνα πριν

Biden, Harris hail Medicare drug price cuts that will save billions

UPDATE 7-Biden, Harris hail Medicare drug price cuts that will save billions Adds hyperlinks By Jeff Mason, Patrick Wingrove and Trevor Hunnicutt LARGO, Maryland/WASHINGTON, Aug 15 (Reuters) - The United States has negotiated down the prices of 10 top-selling prescription drugs used by Medicare by as much as 79%, hoping to save $6 billion in the first year as part of a plan hailed on Thursday by President Joe Biden with the aim to ease anger about high prices ahead of November elections.
A
A
P
Reuters - 1 μήνα πριν

U.S. Announces Final Negotiated Medicare Drug Prices For 10 Medicines

BRIEF-U.S. Announces Final Negotiated Medicare Drug Prices For 10 Medicines Aug 15 (Reuters) - U.S. Centers for Medicare & Medicaid Services: U.S. ANNOUNCES FINAL NEGOTIATED MEDICARE DRUG PRICES FOR 10 MEDICINES U.S. CMS: AGREED TO NEGOTIATED PRICE FOR 30- DAY SUPPLY FOR CY 2026 FOR MERCK'S JANUVIA IS $113.00 U.S. CMS: AGREED TO NEGOTIATED PRICE FOR 30- DAY SUPPLY FOR CY 2026 FOR BRISTOL MYERS' ELIQUIS AT $231 U.S.
A
A
N
P
Reuters - 1 μήνα πριν

US announces prices in Medicare drug negotiations

US announces prices in Medicare drug negotiations Aug 15 (Reuters) - The U.S. announced the final prices of its first ever negotiation over prescription drugs on Thursday, with Merck's MRK.N diabetes drug Januvia seeing the steepest percentage cut at 79%. The government negotiated prices for 10 of the most expensive medicines for its Medicare program serving Americans age 65 or older and the disabled, which covers 66 million people.
A
P
Reuters - 1 μήνα πριν

US expects $6 bln savings from first Medicare drug price negotiations

US expects $6 bln savings from first Medicare drug price negotiations By Patrick Wingrove and Trevor Hunnicutt WASHINGTON, Aug 15 (Reuters) - The U.S. government will save $6 billion in the first year from lower prices the Biden administration negotiated on 10 top-selling prescription drugs for the Medicare health program for older Americans, officials said on Thursday.
A
P
Reuters - 1 μήνα πριν

Top Medicare drugs headed for price cuts

FACTBOX-Top Medicare drugs headed for price cuts By Patrick Wingrove Aug 15 (Reuters) - The Biden administration selected 10 prescription medicines for unprecedented price negotiations by the Medicare health program for older Americans that covers 66 million people. Below are details on the drugs, including their gross cost to Medicare between May 2022 and June 2023: Eliquis Blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N has been one of the most expensive drugs for the Me
A
A
N
P
Reuters - 1 μήνα πριν

Amid an uncertain landscape, high quality may offer stable ground

LIVE MARKETS-Amid an uncertain landscape, high quality may offer stable ground Dow and S&P 500 climb, Nasdaq off ~0.2% Financials lead S&P 500 sector gainers; Comm Svcs weakest group Euro STOXX 600 index up ~0.5% Dollar slips; gold, crude both off ~1%; bitcoin off >2% U.S. 10-Year Treasury yield dips to ~3.82% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
G
K
N
V
G
U
U
F
I
S
U
A
G
B
Reuters - 1 μήνα πριν

Amgen sues Samsung biotech unit over bone drug copies

Amgen sues Samsung biotech unit over bone drug copies By Blake Brittain Aug 13 (Reuters) - Amgen AMGN.O has sued Samsung's biologics unit 207940.KS in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva. Amgen's lawsuit against Samsung Bioepis, filed on Monday, said the biosimilars would infringe 34 patents covering Amgen drugs.
A

Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.